November 27, 2019 / 5:25 AM / 8 months ago

Swiss stocks - Factors to watch on Nov. 27

ZURICH/BERLIN, Nov 27 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1% higher at 10,521 points on Wednesday, according to premarket indications by bank Julius Baer.

Here are some of the main factors that may affect Swiss stocks on Wednesday:


The Swiss-listed private equity company is thinking about selling U.K. software maker Civica, Bloomberg reported.


The food company said it will use a Nutri-Score food labelling on its products to classify them according to their nutitrional profile, starting next year. The labelling will be used on its products in Austria, Belgium, France and Germany, it said.


* Unlisted Gategroup confirmed it was in discussions with Lufthansa about buying LSG's European operations.

* Lonza said it has signed a strategic collaboration with DiNAQOR to advance gene therapy programs for patients with monogenic cardiomyopathies.

* New Value said it decided to sell all shares in Sensimed, which is going through a fire sale in an effort to avoid bankruptcy.

* Stadler Rail said it sold FLIRT trains to Azerbaijan for 115 million euros

* Aevis Victoria said it is buying hotel properties from Credit Suisse, including the company that manages the Intercontinental Hotel in Davos

* Evolva Holding said it has proposed Beat In-Albon as its new chairman

* Edisun Power said it raised nearly 52 million Swiss francs in a capital increase

* Alpiq said its final day of trading on the SIX Swiss Exchange will be Dec. 16 prior to its delisting

* MCH Group said a shareholder group had asked for an extraordinary general meeting where it wants to push through a special examination of the company's strategy, among other things, as the company faces challenges with events including its Baselworld watch fair


CLARIANT - Credit Suisse reinstates coverage with "outperform" rating and 24 Sfr target price

LANDIS & GYR: Credit Suisse raised its target price to 114 francs from 95 francs

VIFOR PHARMA: Credit Suisse raised its target price to 192 francs from 167 francs after the pharma company said on Tuesday that a trial of a key medicine had met its goal


* Swiss November investor sentiment due at 0900 GMT (Reporting by Zurich newsroom and Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below